Clinical Trial Update: Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus [Phase 2]

View source ↗

Summary

Phase 2 trial results for trabectedin in patients with advanced, persistent, or recurrent uterine leiomyosarcoma have been posted. The study status is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Leiomyosarcoma

Drugs mentioned

• Yondelis (trabectedin)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2017-12-12